[A17-18] Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 19.10.2017
Project no.:
A17-18
Commission:
Commission awarded on 27.04.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Muscles, bones and joints
Moderate to severe rheumatoid arthritis in adult patients with insufficient response to prior treatment
For 4 questions added benefit not proven. In one subgroup (patients with unfavourable prognosis pretreated once, ≤ 65 years) hint of lesser benefit versus adalimumab)
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A18-52 | Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-51 | Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A18-28 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
| A17-43 | Tofacitinib (rheumatoid arthritis) - Addendum to Commission A17-18 | Commission completed |
| A21-165 | Tofacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-121 | Tofacitinib (jPsA and pJIA) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-115 | Tofacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
Federal Joint Committee (G-BA)
2017-10-19 A G-BA decision was published.